If you are talking about single-brand drugs generally in the F1 category, then, as I mentioned before, the process for listing those drugs will remain with PBAC and they will only be listed if they are the most cost-effective and medically efficacious drugs. Clearly, they would not be listed by PBAC or recommended for listing by PBAC if they were far more expensive than the United Kingdom because the market would not operate like that as they would not be the most cost-effective option.